SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets open in 6 hrs 51 mins

Sanofi (SNY)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
40.52-0.14 (-0.34%)
At close: 4:02 PM EST
People also watch:
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close40.66
Open40.67
Bid40.47 x 200
Ask40.55 x 100
Day's Range40.01 - 40.66
52 Week Range36.81 - 44.50
Volume2,760,620
Avg. Volume2,602,239
Market Cap104.57B
Beta0.83
PE Ratio (TTM)23.55
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.66 (4.16%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters48 minutes ago

    EU regulator accepts Sanofi/Regeneron's Dupixent product for review

    The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday. Dupixent is aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. If cleared by regulators, Dupixent would be the first approved systemic treatment for eczema, which in severe cases produces infection-prone rashes and a constant itch as bad as poison ivy.

  • PR Newswire2 hours ago

    Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

    TARRYTOWN, N.Y. and PARIS, Dec. 8, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) immune response, which is believed to be a major driver in the pathogenesis of the disease. The objective of the studies was to evaluate Dupixent as monotherapy (SOLO 1 and SOLO 2) and in concomitant administration with topical corticosteroids (CHRONOS) in adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies.

  • 2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November
    Motley Fool14 hours ago

    2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November

    Alnylam Pharmaceuticals rebounded in a big way last month.